JPS6372691A - Hydrated cephalosporin crystal for oral administration - Google Patents

Hydrated cephalosporin crystal for oral administration

Info

Publication number
JPS6372691A
JPS6372691A JP61216260A JP21626086A JPS6372691A JP S6372691 A JPS6372691 A JP S6372691A JP 61216260 A JP61216260 A JP 61216260A JP 21626086 A JP21626086 A JP 21626086A JP S6372691 A JPS6372691 A JP S6372691A
Authority
JP
Japan
Prior art keywords
crystals
water
crystal
acid
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61216260A
Other languages
Japanese (ja)
Other versions
JPH0717651B2 (en
Inventor
Yoshio Hamashima
浜島 好男
Kyoji Minami
南 恭二
Takazo Kawada
享三 河田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to JP21626086A priority Critical patent/JPH0717651B2/en
Priority to NZ220764A priority patent/NZ220764A/en
Priority to GB8715064A priority patent/GB2192183B/en
Priority to NL8701507A priority patent/NL193136C/en
Priority to GR871014A priority patent/GR871014B/en
Priority to IE173887A priority patent/IE59613B1/en
Priority to NO872729A priority patent/NO170889C/en
Priority to DK336487A priority patent/DK161080C/en
Priority to SE8702705A priority patent/SE466257B/en
Priority to IL83059A priority patent/IL83059A/en
Priority to IT8767566A priority patent/IT1211469B/en
Priority to PL1987266567A priority patent/PL159180B1/en
Priority to US07/068,333 priority patent/US4812561A/en
Priority to FR878709316A priority patent/FR2601014B1/en
Priority to AT1658/87A priority patent/AT392472B/en
Priority to SU874202961A priority patent/SU1560057A3/en
Priority to CH2482/87A priority patent/CH672788A5/de
Priority to FI872903A priority patent/FI89052C/en
Priority to HU872992A priority patent/HU200777B/en
Priority to ES8702189A priority patent/ES2004952A6/en
Priority to BE8700740A priority patent/BE1001691A4/en
Priority to AR87308050A priority patent/AR243893A1/en
Priority to KR1019870007019A priority patent/KR950005302B1/en
Priority to CN91105982A priority patent/CN1036632C/en
Priority to CA000541183A priority patent/CA1283405C/en
Priority to DE3745094A priority patent/DE3745094B4/en
Priority to DE19873721913 priority patent/DE3721913A1/en
Priority to PH35485A priority patent/PH24474A/en
Priority to AU75040/87A priority patent/AU594167B2/en
Priority to CN87105009A priority patent/CN1015106B/en
Priority to ES8703123A priority patent/ES2008759A6/en
Priority to SU874203950A priority patent/RU1829932C/en
Publication of JPS6372691A publication Critical patent/JPS6372691A/en
Priority to US07/275,093 priority patent/US4933443A/en
Priority to US07/478,278 priority patent/US5017380A/en
Priority to AT0045890A priority patent/AT396652B/en
Priority to NO911964A priority patent/NO303264B1/en
Priority to NO921401A priority patent/NO921401D0/en
Priority to FI923126A priority patent/FI95349C/en
Priority to HK478/93A priority patent/HK47893A/en
Publication of JPH0717651B2 publication Critical patent/JPH0717651B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

NEW MATERIAL:7beta-[(Z)-2-(2-aimono-4-thiazolyl)-4-carboxy-2-butenoylamino ]-3- cephem-4-carboxylic acid hydrate crystal exhibiting the X-ray diffraction pattern shown in the table. USE:A preventive and remedy for bacterial infection diseases. PREPARATION:An acidic aqueous solution of 7beta-[(Z)-2-(2-amino-4-thiazolyl)-4- carboxy-2-butenoylamino]-3-cephem-4-carboxylic acid is adjusted to isoelectric point or thereabout and the precipitated hydrated crystal is dried in an inert gas having a relative humidity of >=15% under nearly normal temperature and pressure condition.

Description

【発明の詳細な説明】 [目的・技術分野] この発明は7β−[(Z)−2−(2−アミノ−4−チ
アゾリル)−4−カルボキシ−2−ブテノイルアミノコ
−3−セフエム−4−カルボン酸(以下7432−3と
称する)の安定な水和物結晶を提供することを目的とす
る。7432−3は例えば細菌感染症を予防または治療
するH的に使用できる経口セファロスポリン剤である。
Detailed Description of the Invention [Objective/Technical Field] The present invention relates to 7β-[(Z)-2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylaminoco-3-cepheme An object of the present invention is to provide a stable hydrate crystal of -4-carboxylic acid (hereinafter referred to as 7432-3). 7432-3 is an oral cephalosporin that can be used, for example, to prevent or treat bacterial infections.

[先行技術・解決すべき課題] 特開昭60−78987号に記載されているこの化合物
は常法により五酸化溝上減圧乾燥し、無水物としていた
ために比較的不安定であって、長期保存はできなかった
。この化合物を医薬として利用するためには安定な物質
が必要であった。
[Prior Art/Problem to be Solved] This compound described in JP-A No. 60-78987 was dried under reduced pressure on a pentoxide groove by a conventional method to form an anhydride, and therefore is relatively unstable and cannot be stored for a long time. I couldn't. In order to utilize this compound as a medicine, a stable substance was required.

[発明の概要] 発明者は安定性向上法を種々検討した結果、特定の条件
下に製造した?432−5の水和物結晶が一定のX!1
回折像を示し、化学的に安定で、長期間保存できること
を発見し、この発明を完成した。
[Summary of the invention] As a result of examining various methods for improving stability, the inventor produced the product under specific conditions. The hydrate crystal of 432-5 has a certain X! 1
They discovered that it shows a diffraction pattern, is chemically stable, and can be stored for a long period of time, and completed this invention.

[結晶の性状] この7432−8水和物結晶は微黄白色ないし淡黄白色
の微結晶性粉末である。
[Crystal Properties] This 7432-octahydrate crystal is a slightly yellowish white to pale yellowish white microcrystalline powder.

元素分析値は2分子の水を含み、結晶化条件、乾燥条件
などに応じてきらに約1分子までの水を含む7432−
3の水和物の理論値に一致する。
The elemental analysis value is 7432-, which contains 2 molecules of water and up to about 1 molecule of water depending on crystallization conditions, drying conditions, etc.
This agrees with the theoretical value of the hydrate of No. 3.

カール・フィッシャー法で測定した含水率も7〜14%
(特に8.7〜12.5%)で、2〜3分子の結晶水を
含むことを示す。
Moisture content measured by Karl Fischer method is also 7-14%
(especially 8.7 to 12.5%), indicating that it contains 2 to 3 molecules of water of crystallization.

常圧で測定した熱分析曲線は1分子目および2分子目の
水は140°C付近まで保持されるが、3分子目までの
水は30〜60℃付近までに脱離することを示す。
The thermal analysis curve measured at normal pressure shows that the first and second molecules of water are retained up to around 140°C, but the water up to the third molecule is desorbed at around 30 to 60°C.

以上の事実から、3分子目の水は結晶構造内での結合力
が弱く、加熱、減圧などによって簡単に脱離するものと
説明されている。
Based on the above facts, it is explained that the third molecule of water has a weak binding force within the crystal structure and is easily desorbed by heating, reduced pressure, etc.

上記含水範囲(結晶水2〜3分子の範囲)にある水和物
結晶はいずれも下記XwA回折像を示す。
All hydrate crystals in the above water content range (range of 2 to 3 molecules of crystal water) show the following XwA diffraction pattern.

このX線回折像は以下の条件での測定した。This X-ray diffraction image was measured under the following conditions.

X線二波長λ−1,5418人、(銅にα)(Nミーフ
ィルター)40kV−20mA格子間隔dは人単位で、
相対強度1/1.は20.95人の強度を基準とした百
分率で示す。
X-ray dual wavelength λ - 1,5418 people, (α for copper) (N Mee filter) 40 kV - 20 mA Grid spacing d is in units of people,
Relative strength 1/1. is expressed as a percentage based on the strength of 20.95 people.

(以下余白) この発明の水和物結晶では7位側鎖における幾何異性体
の比率は原料における幾何異性体の比率には関係なく主
成分はシスすなわち2異性体で、96〜100%(特に
99.0〜99.8%)の幾何異性体純度が保持される
(Space below) In the hydrate crystal of this invention, the ratio of geometric isomers in the 7-position side chain is independent of the ratio of geometric isomers in the raw material, and the main component is cis, that is, 2 isomers, and is 96 to 100% (especially A geometric isomeric purity of 99.0-99.8%) is maintained.

この発明の水和物結晶は臭化カリウム錠剤法で測定する
と赤外線吸収スペクトルには無水物と異なり1700c
m−’に強い吸収が認められる。
When the hydrate crystals of this invention are measured by the potassium bromide tablet method, the infrared absorption spectrum shows 1700C, unlike the anhydride.
A strong absorption is observed at m-'.

[製造法コ (1)概論 この7432−3水和物結晶は以下の方法で製造する。[Manufacturing method] (1) Overview This 7432-3 hydrate crystal is produced by the following method.

原料である7432−3を酸性水性溶液とし、室温付近
(特に0〜70°C)で等1点付近(特にpH1,5〜
5.(3)に!I11整して結晶を析出させる。要すれ
ば結晶を熟成させるために攪拌したのち、含水結晶を分
離する。これを相対湿度15%以上の不活性気体中、常
温付近で常圧乾燥すれば目的とする水和物結晶を製造す
ることができる。
The raw material 7432-3 is made into an acidic aqueous solution, and the pH is adjusted to around 1 point (especially at pH 1.5 to 70°C) at room temperature (especially 0 to 70°C).
5. (3)! I11 is adjusted to precipitate crystals. After stirring to ripen the crystals if necessary, the water-containing crystals are separated. By drying this in an inert gas with a relative humidity of 15% or more at around room temperature under normal pressure, the desired hydrate crystal can be produced.

(2)原料 原料である7432−8は含水でも無水でもよい、また
、遊離化合物、アミノ基における塩(酸付加塩など)、
カルボキシ基における塩(アルカリ金属塩など)などで
もよい、yX料に水溶性塩(アルカリ金属塩、塩酸塩な
ど)を用い、前処理(精製、シス異性体化、単離など)
と組合せて下記の酸性水性溶液調製処理をするのは好ま
しい態様の一つである。
(2) The raw material 7432-8 may be hydrated or anhydrous, and may also be a free compound, a salt at an amino group (such as an acid addition salt),
Pretreatment (purification, cis isomerization, isolation, etc.) using a water-soluble salt (alkali metal salt, hydrochloride, etc.) for the yX material, which may be a salt at the carboxy group (alkali metal salt, etc.)
One of the preferred embodiments is to perform the following acidic aqueous solution preparation treatment in combination with

(3)酸 酸性水性溶液化処理には原料を酸の水性溶液に溶解する
方法、原料の中性水性溶液に酸を加える方法などがある
。ここに用いる酸としては無機酸(塩酸、硫酸、燐酸な
ど)、カルボン酸(酢酸、リンゴ酸、フマル酸、クエン
酸など)、スルホン酸(メタンスルホン酸、エタンスル
ホン酸、トルエンスルホン酸など)、酸性塩(ジメチル
アミンの塩酸塩、原料の塩酸塩など)など、原料を酸性
水性溶液とし得る水溶性の酸であればいかなる酸でも利
用できる。酸の量は0〜20モル当量(特に1〜10モ
ル当量)が好ましい。原料が鉱酸塩などの場合にはここ
に用いる酸として原料自身の酸性を利用することもでき
る。
(3) Acid The acidic aqueous solution treatment includes a method of dissolving the raw material in an aqueous solution of an acid, a method of adding an acid to a neutral aqueous solution of the raw material, and the like. Acids used here include inorganic acids (hydrochloric acid, sulfuric acid, phosphoric acid, etc.), carboxylic acids (acetic acid, malic acid, fumaric acid, citric acid, etc.), sulfonic acids (methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, etc.), Any water-soluble acid, such as acid salts (dimethylamine hydrochloride, raw material hydrochloride, etc.) that can convert the raw material into an acidic aqueous solution, can be used. The amount of acid is preferably 0 to 20 molar equivalents (especially 1 to 10 molar equivalents). When the raw material is a mineral salt or the like, the acidity of the raw material itself can be used as the acid used here.

(4)補助溶媒 水性溶液には補助溶媒としてアルコール(メタノール、
エタノール、インプロパツール、第3級ブタノール、メ
トキシエタノールなど)、アミド(ジメチルホルムアミ
ドなど)、ニトリル(アセトニトリルなど)、スルホキ
シド(ジメチルスルホキシドなど)、エーテル(ジオキ
サン、テトラヒドロフラン、ジメトキシエタンなど)、
ケトン(アセトン、メチルエチルケトンなど)など、水
と混和しうる有機溶媒O%〜70%を含有していてもよ
い、  − (5)濃度 酸性水性溶液中の原料濃度は2.0〜15.0%(特に
3.0〜5.0%)が好ましい。
(4) Co-solvent Alcohol (methanol,
ethanol, impropatol, tertiary butanol, methoxyethanol, etc.), amides (dimethylformamide, etc.), nitriles (acetonitrile, etc.), sulfoxides (dimethylsulfoxide, etc.), ethers (dioxane, tetrahydrofuran, dimethoxyethane, etc.),
May contain 0% to 70% of water-miscible organic solvents such as ketones (acetone, methyl ethyl ketone, etc.) - (5) Concentration The raw material concentration in the acidic aqueous solution is 2.0 to 15.0%. (especially 3.0 to 5.0%) is preferable.

(6)中和 酸性水性溶液を室温付近(約0〜70℃、特に10〜4
5°C)で等電点付近(pH約1.5〜5.0、特に2
.0〜3.5)に調整する場合、中和に用いる塩基は酸
性水性溶液の酸性を所定のpHまで中和できるものであ
れば固体でも液体でもよい0代表的塩基としては有機塩
基(トリエチルアミンなど)、無機塩基(アンモニア、
炭酸ナトリウム、炭酸カリウム、炭酸水素ナトリウム、
炭酸水素カリウムなど)などのうち、水溶性の塩基を利
用し易いが、これらに限定されるものではない0例えば
ヒドロキシド型アニオン交換樹脂など水不溶性塩基を利
用することもできる。
(6) Neutralized acidic aqueous solution near room temperature (approximately 0 to 70℃, especially 10 to 4℃)
5°C) near the isoelectric point (pH approximately 1.5 to 5.0, especially 2
.. 0 to 3.5), the base used for neutralization may be solid or liquid as long as it can neutralize the acidity of the acidic aqueous solution to a predetermined pH. Representative bases include organic bases (such as triethylamine). ), inorganic bases (ammonia,
Sodium carbonate, potassium carbonate, sodium bicarbonate,
Water-soluble bases such as potassium hydrogen carbonate (potassium hydrogen carbonate, etc.) are easy to use, but are not limited to these.For example, water-insoluble bases such as hydroxide type anion exchange resins can also be used.

(7)晶出・熟成 結晶を晶出、熟成させるためには等電点付近に調整した
溶液を0〜70℃(特に5〜35°C)で10分〜50
時間攪拌する。
(7) Crystallization/Aging To crystallize and ripen crystals, heat a solution adjusted to around the isoelectric point at 0 to 70°C (especially 5 to 35°C) for 10 to 50 minutes.
Stir for an hour.

(8)乾燥 乾燥には攪拌、粉体流動条件などにもよるが、相対湿度
15%以上の不活性気体(空気、窒素、炭酸ガスなど)
中、常温付近(約0〜60°C)での常圧乾燥(静置乾
燥、通気乾燥、通風乾燥、流動層乾燥など)など緩和な
条件が好ましい。
(8) Drying For drying, use an inert gas (air, nitrogen, carbon dioxide, etc.) with a relative humidity of 15% or more, depending on stirring, powder flow conditions, etc.
Mild conditions such as normal pressure drying (stationary drying, ventilation drying, ventilation drying, fluidized bed drying, etc.) at medium to room temperature (approximately 0 to 60° C.) are preferred.

実験室規模では以下の測定値が得られている。The following measurements have been obtained on a laboratory scale.

密閉静置乾燥の場合、例えば常圧空気中では、相対湿度
15〜50%(特に20〜30%)で温度25〜60″
Cでは1〜8時間後に二水和物に相当する含水率付近で
、また、相対湿度45%以上(特に50〜80%)で空
気温度30℃以下(特に10〜25℃)では1〜8時間
後に三水和物に相当する含水率付近で、脱水がほぼ停止
する。
In the case of sealed stationary drying, for example, in normal pressure air, the relative humidity is 15 to 50% (especially 20 to 30%) and the temperature is 25 to 60".
In C, the water content is around the same as dihydrate after 1 to 8 hours, and at relative humidity of 45% or more (especially 50 to 80%) and air temperature of 30°C or less (especially 10 to 25°C), the water content is 1 to 8. After a period of time, dehydration almost stops at a water content corresponding to trihydrate.

通気、通風乾燥の場合、湿度、粉体流動条件などにもよ
るが、例えば温度25〜40°C1相対湿度50〜60
%の空気を時間対出口温度または時間対出口湿度曲線の
変曲点付近(原料の水分含有率30〜60%の場合には
約2〜10時間)まで送風乾燥すれば;水和物結晶(含
水率8〜8.8%)を製造できる。
In the case of ventilation and ventilation drying, it depends on the humidity, powder flow conditions, etc., but for example, the temperature is 25-40°C, the relative humidity is 50-60°C.
% air to around the inflection point of the time versus outlet temperature or time versus outlet humidity curve (approximately 2 to 10 hours when the moisture content of the raw material is 30 to 60%); hydrate crystals ( water content of 8 to 8.8%).

流動層乾燥の場合、送風速度などの条件にもよるが、例
えば温度10〜35℃(特に20〜30’C)、相対湿
度50〜60%の空気を時間対出口温度曲線または時間
対出口湿度曲線の第一変曲点(原料の水分含有率30〜
60%の場合には約1時間)まで送風乾燥すれば三水和
物結晶を、第二変曲点(原料の水分含有率30〜60%
の場合には約1.5時間)まで送風乾燥すれば三水和物
結晶を製造できる。
In the case of fluidized bed drying, it depends on conditions such as air blowing speed, but for example, air at a temperature of 10 to 35°C (particularly 20 to 30'C) and a relative humidity of 50 to 60% is dried using a time versus outlet temperature curve or a time versus outlet humidity curve. The first inflection point of the curve (moisture content of raw materials 30~
If the trihydrate crystal is dried with air until it reaches the second inflection point (the moisture content of the raw material is 30 to 60%),
Trihydrate crystals can be produced by drying with air for up to about 1.5 hours).

大量製造には通風乾燥、通気乾燥、流動層乾燥などを用
いる。
For mass production, ventilation drying, ventilation drying, fluidized bed drying, etc. are used.

流動層乾燥の場合、含水結晶重量当り送風速度などの条
件にもよるが、−例では温度10〜60℃(特に20〜
30℃)、相対湿度20〜80%(特に50〜60%)
の空気を出口温度対時間曲線または出口湿度対時間曲線
の第一変曲点付近(原料の水分含有率30〜60%の場
合には約1〜5時間)まで送風乾燥すれば三水和物結晶
を、第二変曲点付近(w、料の水分含有率30〜60%
の場合には約3〜7時間)まで送風乾燥すれば三水和物
結晶を製造できる。
In the case of fluidized bed drying, although it depends on the conditions such as the air speed per water-containing crystal weight, in some cases the temperature is 10 to 60°C (particularly 20 to 60°C).
30℃), relative humidity 20-80% (especially 50-60%)
If the air of The crystals were heated near the second inflection point (w, the water content of the material was 30 to 60%).
trihydrate crystals can be produced by drying with air for about 3 to 7 hours).

約60″C以上の加熱乾燥、乾燥剤による乾燥、減圧乾
燥など、通常の乾燥条件(例えば、0.Ol mmHg
、塩化カルシウム上25〜28℃では3時間以内に含水
率1.5〜4.8%まで、また乾燥窒素ガス通気では2
5°Cで30分間以内に含水率1.08%まで脱水され
た)では結晶水2分子以下まで脱水きれ、安定な製品は
得られない。
Normal drying conditions (e.g., 0.Ol mmHg
, moisture content up to 1.5-4.8% within 3 hours at 25-28°C on calcium chloride, and 2% with dry nitrogen gas aeration.
(dehydrated to a water content of 1.08% within 30 minutes at 5°C), dehydration is completed to less than 2 molecules of crystal water, and a stable product cannot be obtained.

[安定性] この発明の水和物結晶の安定性を50℃での加速試験で
確認した結果、1ケ月残存率が97.6%であり、無水
物結晶の測定値73.6%と比較して、著しく安定であ
ることが判明した。
[Stability] As a result of confirming the stability of the hydrate crystal of this invention in an accelerated test at 50°C, the one-month survival rate was 97.6%, compared with the measured value of 73.6% for the anhydride crystal. It was found to be extremely stable.

[用途] この発明の水和物結晶は経口投与製剤(特にカプセル、
顆粒剤、錠剤など)として細菌感染症の予防、治療に利
用することができる。
[Applications] The hydrate crystals of this invention can be used in oral preparations (especially capsules,
It can be used in the form of granules, tablets, etc. for the prevention and treatment of bacterial infections.

(以下余白) 以下に実施例を示してこの発明の詳細な説明する。含水
率はカール・フィッシャー法によって測定した値である
(The following is a blank space.) The present invention will be described in detail below with reference to Examples. The moisture content is a value measured by the Karl Fischer method.

実施例1 粗7432−S結晶25gを6N−塩酸75m1にとか
し、15〜20℃に1時間放置して塩酸塩を析出させた
のち、結晶を濾取する。これを濃塩酸1滴を加えたアセ
トニトリル75m1で洗い、乾燥すれば、7432−5
・塩酸塩−水和物18gを得る。
Example 1 25 g of crude 7432-S crystals were dissolved in 75 ml of 6N hydrochloric acid and left at 15 to 20° C. for 1 hour to precipitate the hydrochloride, and then the crystals were collected by filtration. If this is washed with 75ml of acetonitrile to which one drop of concentrated hydrochloric acid is added and dried, 7432-5
- Obtain 18 g of hydrochloride hydrate.

この結晶1.0gを水30m1にとかし、p)(を1.
5として25〜45℃で2.5時間攪拌したのち、析出
する結晶を濾取し、水洗する。結晶を10℃で5時間通
風乾燥すれば7432−8水和物結晶0.9gを得る。
Dissolve 1.0 g of this crystal in 30 ml of water, and add 1.0 g of this crystal to 1.0 g of this crystal.
After stirring for 2.5 hours at 25 to 45°C, precipitated crystals were collected by filtration and washed with water. The crystals are dried with ventilation at 10° C. for 5 hours to obtain 0.9 g of 7432-octahydrate crystals.

含水率:10.2%、幾何異性体比率(シス対トランス
)−98,8:0.8゜ 実施例2 7432−3粗結晶1.17gを第二級ブタノール3m
l・アセトニトリル3ml混液に懸濁し、35%塩酸1
a+1(5モル当量)を加えてとかす、この溶液を第三
級ブタノール3ml・アセトニトリル9ml・水5ml
混液でうすめ、トリエチルアミンを加えてpH2,3に
調整し、30〜35℃で3時間攪拌する。析出する結晶
を分離し、第三級ブタノール・アセトニトリル・水(1
:2:1)混液5mlと水10m1で洗い、25〜30
℃で2時間通気乾燥すれば7432−3水和物結晶1.
06gを得る。含水率:8.75%、幾何異性体比率(
シス対トランス)−99,210,8゜実施例3 7432−3粗結晶1.0gを水8ml・アセトニトリ
ル1ml混液に懸濁し、炭酸水素ナトリウム0.41g
(2モル当量)を加えてとかす。この溶液をメタノール
6mlでうすめ、活性炭0.1gを加え、室温で10分
間攪拌したのち濾過して活性炭を除去する。濾液を6N
−塩酸1.62m1(4,5モル当量)・水3.4ml
・アセトニトリル5ml混液に注入する。混合物のpH
を30%炭酸カリウム溶液でpH2,3にu4N!シ、
40℃で1時間と20〜25℃で1.5時間攪拌する。
Moisture content: 10.2%, geometric isomer ratio (cis vs. trans) -98.8:0.8° Example 2 1.17 g of 7432-3 crude crystals was mixed with 3 m of secondary butanol.
Suspend in 3 ml of acetonitrile mixture, add 1 ml of 35% hydrochloric acid
Add a+1 (5 molar equivalents) and dissolve. This solution is mixed with 3 ml of tertiary butanol, 9 ml of acetonitrile, and 5 ml of water.
Dilute with the mixed solution, add triethylamine to adjust the pH to 2.3, and stir at 30-35°C for 3 hours. Separate the precipitated crystals and mix with tertiary butanol, acetonitrile, water (1
:2:1) Wash with 5ml of the mixture and 10ml of water,
After air drying at ℃ for 2 hours, 7432-3 hydrate crystals 1.
Obtain 0.6g. Moisture content: 8.75%, geometric isomer ratio (
cis vs. trans) -99,210,8゜Example 3 1.0 g of 7432-3 crude crystals was suspended in a mixture of 8 ml of water and 1 ml of acetonitrile, and 0.41 g of sodium hydrogen carbonate was added.
(2 molar equivalents) and dissolve. This solution was diluted with 6 ml of methanol, 0.1 g of activated carbon was added, and after stirring at room temperature for 10 minutes, the activated carbon was removed by filtration. The filtrate is 6N
-Hydrochloric acid 1.62ml (4.5 molar equivalent)/water 3.4ml
- Pour into 5 ml of acetonitrile mixture. pH of the mixture
to pH 2.3 with 30% potassium carbonate solution. C,
Stir at 40°C for 1 hour and at 20-25°C for 1.5 hours.

析出する結晶を濾取し、メタノール・アセトニトリル・
水(1:1:2)混液5mlと水2On+1とメタノー
ル5mlとで順次洗い、20〜25℃で1.5時間通風
乾燥すれば7432−3淡黄白色水和物結晶0.876
gを得る。含水率:9.35%。
Collect the precipitated crystals by filtration and add methanol, acetonitrile,
Wash with 5 ml of water (1:1:2) mixture, 2 On+1 water, and 5 ml of methanol in sequence, and dry with ventilation at 20 to 25°C for 1.5 hours to obtain 7432-3 pale yellow-white hydrate crystals.
get g. Moisture content: 9.35%.

幾何異性体比率(シス対トランス)−99,610,4
゜ 実施例4 15〜20℃の炭酸水素ナトリウム1.848g(3モ
ル当量)の水42m1溶液に7432−8粗結晶4.6
6gを加えてと力)す、この溶液にアセトニトリル19
m1、活性アルミナ2.34gと活性炭0.466gを
加え、15〜20℃で30分間撹拌したのち濾過して活
性炭とアルミナを途去する。濾液をアセトニトリル37
m1・62%硫v3.95g・水28m1混涜に注入す
る。混合物に20〜25°Cで30%炭酸カリウム溶液
を加えてpH3,0に調整し、同温度で30分間攪拌す
る。析出する結晶を濾取し、20〜25°Cで2〜3時
間通気乾燥すれば7432−S水和物結晶4.384g
を得る。含水率:12.2%、幾何異性体比率(シス対
トランス)−99,610゜4゜ 同様の条件下、7432−81.Ogの炭酸水素ナトリ
ウム水溶液12m1を活性アルミナと活性炭で処理した
溶液に溶媒(水、イソプロパツールまたはアセトニトリ
ル)6mlと85%燐酸8モルを加えて酸性とし、20
〜25℃で30%炭酸カリウム溶液を加えてpH3,0
にm整し、同温で30分間攪拌する。析出する結晶を濾
取し、20〜25℃で2〜3時間通気乾燥すれば?43
2−5水和物結晶約0.90gを得る。含水率:11.
0%、幾何異性体比率(シス対トランス)−99,2〜
99 、710 、8〜0.3゜同様の条件下、燐酸の
代わりにメタンスルホン#4モルを用い、以下前記と同
様に処理すれば7432−3水和物結晶0.879gを
得る。含水率:11.4%0ga何異性体比率(シス対
トランス)−99,610,4゜ 実施例5 7432−8粗結晶2.0gをジメトキシエタン18m
1・エタノール2ml混液に懸濁し、2〜5℃で6N−
塩No 、89m1(1,3モル当量)を加え、同温で
2時間攪拌する。析出する塩酸塩の結晶を濾取し、ジメ
トキシエタン・エタノール(9:1)混液10m1とア
セトニトリル10m1で順次洗い、25〜30℃で2時
間真空乾燥すれば塩酸塩1.878gを得る。
Geometric isomer ratio (cis vs. trans) -99,610,4
゜Example 4 4.6 7432-8 crude crystals were added to a solution of 1.848 g (3 molar equivalents) of sodium hydrogen carbonate in 42 ml of water at 15-20°C.
Add 6g of acetonitrile to this solution.
ml, 2.34 g of activated alumina and 0.466 g of activated carbon were added, stirred at 15-20°C for 30 minutes, and then filtered to remove activated carbon and alumina. Dilute the filtrate with acetonitrile 37
Pour into a mixture of 1ml of 62% sulfur v3.95g and 28ml of water. A 30% potassium carbonate solution was added to the mixture at 20-25°C to adjust the pH to 3.0, and the mixture was stirred at the same temperature for 30 minutes. If the precipitated crystals are collected by filtration and air-dried at 20-25°C for 2-3 hours, 4.384 g of 7432-S hydrate crystals will be obtained.
get. Moisture content: 12.2%, geometric isomer ratio (cis vs. trans) -99,610°4° Under similar conditions, 7432-81. 6 ml of a solvent (water, isopropanol or acetonitrile) and 8 mol of 85% phosphoric acid were added to a solution of 12 ml of an aqueous solution of Og sodium hydrogen carbonate treated with activated alumina and activated carbon to make it acidic.
pH 3.0 by adding 30% potassium carbonate solution at ~25°C
and stir for 30 minutes at the same temperature. What if the precipitated crystals are collected by filtration and air-dried at 20-25°C for 2-3 hours? 43
Approximately 0.90 g of 2-5 hydrate crystals are obtained. Moisture content: 11.
0%, geometric isomer ratio (cis vs. trans) -99.2 ~
99, 710, 8-0.3° Under the same conditions, using #4 mol of methanesulfone instead of phosphoric acid, the same procedure as above was performed to obtain 0.879 g of 7432-3 hydrate crystals. Moisture content: 11.4% 0ga What isomer ratio (cis vs. trans) -99,610,4゜Example 5 2.0g of 7432-8 crude crystals was added to 18ml of dimethoxyethane.
1. Suspend in 2 ml of ethanol mixture and incubate with 6N-
Add 89 ml (1.3 molar equivalents) of salt No. 2 and stir at the same temperature for 2 hours. The precipitated hydrochloride crystals are collected by filtration, washed successively with 10 ml of dimethoxyethane/ethanol (9:1) mixture and 10 ml of acetonitrile, and vacuum dried at 25-30°C for 2 hours to obtain 1.878 g of hydrochloride.

この結晶1.0gをメタノール6ml・水5ml混液に
懸濁し、炭酸水素ナトリウム0.61g(3モル当量)
を加えてとかす、この溶液に活性炭0.1gを加え、2
5〜30℃で10分間攪拌したのち濾過して活性炭を除
く、濾液を35%塩酸1.01!l1l(4モル当量)
・水3ml・アセトニトリル6ml混液に注入し、30
%炭酸カリウム溶液を加えてpH3,0としたのも25
〜30℃で30分間と5〜7℃で1時間攪拌する。析出
する結晶を濾取し、エタノール5mlと水10m1で順
次洗い、20〜25℃で2時間通風乾燥すれば7432
−S水和物結晶0.82g′+得る。含水率:10.6
%、幾何異性体比率(シス対トランス)−99、510
、5゜ 実施例6 炭酸水素ナトリウム1.3g(2,2モル当量)を水1
8m1にとかし、これに7432−5粗結晶3.0gを
加えてとかす、この溶液に活性アルミナ1.5gと活性
炭0.3gを加え、20〜25°Cで30分間攪拌した
のち濾過して活性炭とアルミナを除<、a掖をリンゴ酸
10モル当量の水17m1・アセトニトリル36m1溶
液に注入し、20〜25℃で30%炭酸カリウム溶液を
加えてpH3,0に調整し、30分間攪拌する。析出す
る結晶を濾取し、25〜30″Cで2時間通気乾燥すれ
ば7432−8水和物結晶2.665gを得る。含水率
:11.7%、幾何異性体比率(シス対トランス)−9
9,110,9゜ ここに前記リンゴ酸10モルをフマル酸10モル当量に
代えても同一の水和物結晶(含水率10.1%)を得る
1.0 g of this crystal was suspended in a mixture of 6 ml of methanol and 5 ml of water, and 0.61 g (3 molar equivalents) of sodium hydrogen carbonate was added.
Add 0.1g of activated carbon to this solution and dissolve.
After stirring for 10 minutes at 5-30°C, filter the activated carbon to remove the filtrate, which is 35% hydrochloric acid 1.01% l1l (4 molar equivalents)
・Pour into a mixture of 3 ml of water and 6 ml of acetonitrile, and add 30
25% potassium carbonate solution was added to adjust the pH to 3.0.
Stir at ~30°C for 30 minutes and at 5-7°C for 1 hour. The precipitated crystals are collected by filtration, washed sequentially with 5 ml of ethanol and 10 ml of water, and dried with ventilation at 20-25°C for 2 hours to obtain 7432.
-0.82 g'+ of S hydrate crystals are obtained. Moisture content: 10.6
%, geometric isomer ratio (cis vs. trans) -99, 510
, 5゜Example 6 1.3 g (2.2 molar equivalents) of sodium hydrogen carbonate was added to 1 mol of water.
To this solution, add 3.0 g of 7432-5 crude crystals and dissolve. 1.5 g of activated alumina and 0.3 g of activated carbon are added to this solution, stirred at 20-25°C for 30 minutes, filtered, and dissolved with activated carbon. After removing the alumina, pour the aliquot into a solution of 10 molar equivalents of malic acid in 17 ml of water and 36 ml of acetonitrile, adjust the pH to 3.0 by adding 30% potassium carbonate solution at 20-25°C, and stir for 30 minutes. The precipitated crystals are collected by filtration and air-dried at 25-30"C for 2 hours to obtain 2.665 g of 7432-octahydrate crystals. Water content: 11.7%, geometric isomer ratio (cis vs. trans). -9
9,110,9° Even if 10 moles of malic acid were replaced with 10 mole equivalents of fumaric acid, the same hydrate crystals (water content 10.1%) were obtained.

同様にして7432−31.Ogを炭酸水素ナトリウム
水にとかし、活性アルミナと活性炭で精製した溶液にギ
酸4モル当量を水・アセトニトリル混液に溶かして加え
、以下前記と同様に処理すれば7432−S水和物結晶
0.925gを得る。含水率:12.7%、幾何異性体
比率(シス対トランス)翼99 、810 、2゜ここ
に前記ギ酸添加量を75モル当量まで増加しても同一の
水和物結晶を得る。
Similarly, 7432-31. Dissolve Og in sodium bicarbonate water, add 4 molar equivalents of formic acid dissolved in a mixture of water and acetonitrile to a solution purified with activated alumina and activated carbon, and proceed in the same manner as above to obtain 0.925 g of 7432-S hydrate crystals. get. Moisture content: 12.7%, geometric isomer ratio (cis vs. trans): 99, 810, 2°. Even if the amount of formic acid added was increased to 75 molar equivalents, the same hydrate crystals were obtained.

実施例7 実施例3の方法で製造した未乾燥7432−81gの6
検体をそれぞれ密閉容器にとり、室温での相対湿度を含
水乾燥剤の選択により0%、12%、20%、44%、
57%および75%に固定して6時間放置した。各検体
の水分をカール・フィッシャー法で1ifi11定すれ
ば、それぞれ1.05%、5.83%、8.54%、1
1.21%、12.19%および12.21%の値を示
す。
Example 7 Undried 7432-81g of 6 produced by the method of Example 3
Each sample was placed in a sealed container, and the relative humidity at room temperature was adjusted to 0%, 12%, 20%, 44%, depending on the selection of the water-containing desiccant.
It was fixed at 57% and 75% and left for 6 hours. If the moisture content of each sample is determined by the Karl Fischer method, it will be 1.05%, 5.83%, 8.54%, and 1%, respectively.
Showing values of 1.21%, 12.19% and 12.21%.

相対湿度20%では二水和物(含水率計算値=8.07
%)、44%以上では三水和物(含水率計算値:11.
64%)が主成分であることを示す。
At 20% relative humidity, dihydrate (calculated water content = 8.07
%), and at 44% or more, trihydrate (calculated water content: 11.
64%) is the main component.

この乾燥を30時間まで継続した場合でも相対湿度20
%以上の検体の6〜30時間の間の含水率減少値は0.
2%以下にとどまる。
Even if this drying is continued for up to 30 hours, the relative humidity is 20
% or more, the water content decrease value for 6 to 30 hours is 0.
It remains below 2%.

実施例8 実施例3の方法で製造した未乾燥7432−51gの6
検体をそれぞれ密閉容器にとり、40℃で相対湿度を含
水乾燥剤の選択により20%、44%、57%および7
5%に固定し、1ケ月間放置する。各検体の水分をカー
ル・フィッシャー法で測定すれば、それぞれ7.92%
、10.69%、11.73%および12.4%の値を
示し、室温30時間の値との差は0.5%以内で含水率
は極めて安定している。
Example 8 Undried 7432-51g of 6 produced by the method of Example 3
Each sample was placed in a sealed container, and the relative humidity was adjusted to 20%, 44%, 57%, and 7% by selecting a hydrous desiccant at 40°C.
Fix it at 5% and leave it for one month. If the moisture content of each sample is measured using the Karl Fischer method, each sample will be 7.92%.
, 10.69%, 11.73%, and 12.4%, and the difference from the value at room temperature for 30 hours is within 0.5%, and the moisture content is extremely stable.

特許出願人  塩野義製薬株式会社 代 理 人  弁理士 潮1)ト  。Patent applicant: Shionogi & Co., Ltd. Representative Patent Attorney Ushio 1) G.

Claims (3)

【特許請求の範囲】[Claims] (1)次のX線回折像を示す7β−[(Z)−2−(2
−アミノ−4−チアゾリル)−4−カルボキシ−2−ブ
テノイルアミノ]−3−セフエム−4−カルボン酸水和
物結晶。
(1) 7β-[(Z)-2-(2
-amino-4-thiazolyl)-4-carboxy-2-butenoylamino]-3-cephem-4-carboxylic acid hydrate crystals.
(2)7β−[(Z)−2−(2−アミノ−4−チアゾ
リル)−4−カルボキシ−2−ブテノイルアミノ]−3
−セフエム−4−カルボン酸の酸性水性溶液を等電点付
近に調製して晶出させ、得られる含水結晶を常温常圧付
近で相対湿度15%以上の不活性気体中で乾燥させるこ
とを特徴とする特許請求の範囲(1)の水和物結晶の製
造方法。
(2) 7β-[(Z)-2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylamino]-3
-Preparing an acidic aqueous solution of cefem-4-carboxylic acid near its isoelectric point and crystallizing it, and drying the resulting water-containing crystals in an inert gas with a relative humidity of 15% or more at room temperature and pressure. A method for producing hydrate crystals according to claim (1).
(3)水性溶液から析出した7β−[(Z)−2−(2
−アミノ−4−チアゾリル)−4−カルボキシ−2−ブ
テノイルアミノ]−3−セフエム−4−カルボン酸の含
水結晶を常温常圧付近で相対湿度15%以上の不活性気
体中で乾燥させることを特徴とする特許請求の範囲(1
)の水和物結晶の製造方法。
(3) 7β-[(Z)-2-(2
-Amino-4-thiazolyl)-4-carboxy-2-butenoylamino]-3-cephem-4-carboxylic acid hydrous crystals are dried in an inert gas with a relative humidity of 15% or more at room temperature and pressure. Claims (1)
) method for producing hydrate crystals.
JP21626086A 1986-07-02 1986-09-12 Cefalosporin hydrate crystal for oral administration Expired - Lifetime JPH0717651B2 (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
JP21626086A JPH0717651B2 (en) 1986-09-12 1986-09-12 Cefalosporin hydrate crystal for oral administration
NZ220764A NZ220764A (en) 1986-07-02 1987-06-19 Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
GB8715064A GB2192183B (en) 1986-07-02 1987-06-26 A crystalline oral cephalosporin hydrate and its compositions
NL8701507A NL193136C (en) 1986-07-02 1987-06-26 Crystalline hydrate of an oral cephalosporin derivative, process for its preparation and pharmaceutical product therefrom.
GR871014A GR871014B (en) 1986-07-02 1987-06-29 A crystalline hydrate of oral cephalosporin
IE173887A IE59613B1 (en) 1986-07-02 1987-06-29 A crystalline oral cephalosporin hydrate and its compositions
NO872729A NO170889C (en) 1986-07-02 1987-06-30 PROCEDURE FOR PREPARING A STABLE CRYSTALLINE DIET OR TRIHYDRATE OF 7BETA - ((Z) -2- (2-AMINOTIAZOL-4-YL) -4-CARBOXYBUT-2-ENOYLAMINO) -3-CEFEM-4-CARBOXYL
DK336487A DK161080C (en) 1986-07-02 1987-06-30 CRYSTALLIC HYDRATE OF ORAL USED CEPHALOSPORIN AND PREPARATION
SE8702705A SE466257B (en) 1986-07-02 1987-06-30 CRYSTALLINE HYDRATED BY ORAL CEPHALOSPORIN AND GELATIN HARD Capsule CONTAINING HYDRATE
IL83059A IL83059A (en) 1986-07-02 1987-07-01 Stable hydrate of cephalosporin derivative,process for the preparation thereof and a gelatin capsule composition containing the same
IT8767566A IT1211469B (en) 1986-07-02 1987-07-01 ACID CRYSTALLINE HYDRATE 7 BETA 72 2 AMMINOTHIAZOL 4 IL 4 CARBOSSI BUT 2 ENOILAMMINO 3 CEFEM 4 CARBOXYL PROCEDURE FOR ITS OBTAINED PACKAGING FOR GELATINE CAPSULES CONTAINING SUCH HYDRATE PROCEDURE FOR OBTAINING THIS COMPOSITION
PL1987266567A PL159180B1 (en) 1986-07-02 1987-07-01 Method of obtaining di- and/or trihydrate of 7beta-c/z/-2-/2-amino thiazolyl-4/-4-caroxybutene-2-oiloamino/-3-cephemocarboxylic acid
US07/068,333 US4812561A (en) 1986-07-02 1987-07-01 Crystalline hydrate of oral cephalosporin and its composition
FR878709316A FR2601014B1 (en) 1986-07-02 1987-07-01 CRYSTALLINE HYDRATE OF ORAL CEPHALOSPORIN, COMPOSITION AND PROCESS FOR PREPARING THE SAME
AT1658/87A AT392472B (en) 1986-07-02 1987-07-01 METHOD FOR PRODUCING A STABLE CRYSTALLINE DI- OR TRIHYDRATE OF 7BETA- ((Z) -2- (2-AMINOTHIAZOL-4-YL) -4-CARBOXYBUT-2- ENOYLAMINO) -3-CEPHEM-4-CARBONIC ACID
SU874202961A SU1560057A3 (en) 1986-09-12 1987-07-01 Method of producing crystalline trihydrate or dihydrate or their mixtures of 7b-/(z)-2-(2-aminothiazol-4-yl)-4-carboxybut-2-enoylamino/-3-cephem-4-carbonic acid
CH2482/87A CH672788A5 (en) 1986-07-02 1987-07-01
FI872903A FI89052C (en) 1986-07-02 1987-07-01 EXAMPLE OF FRAMSTATING AV AND CRYSTALLINE HYDRAULIC AV
HU872992A HU200777B (en) 1986-07-02 1987-07-01 Process for producing crystalline cefalosporinhydrate and capsules comprising same
AR87308050A AR243893A1 (en) 1986-07-02 1987-07-02 Crystalline oral cephalosporin hydrate
BE8700740A BE1001691A4 (en) 1986-07-02 1987-07-02 Crystalline hydrate cephalosporin use oral and composition.
ES8702189A ES2004952A6 (en) 1986-07-02 1987-07-02 Crystalline hydrate of oral cephalosporin and its composition
KR1019870007019A KR950005302B1 (en) 1986-07-02 1987-07-02 Crystalline hydrate of oral cephalosporin and its composition
CN91105982A CN1036632C (en) 1986-07-02 1987-07-02 Process for preparing composition containing oral cephalosporin crystal hydrate
CA000541183A CA1283405C (en) 1986-07-02 1987-07-02 Crystalline hydrate of oral cephalosporin and its composition
DE3745094A DE3745094B4 (en) 1986-07-02 1987-07-02 New stable hydrate of 7-butenoyl:amino- cephalosporin derivs. - esp. formulated in soft gelatin capsules sealed with gelatin layer
DE19873721913 DE3721913A1 (en) 1986-07-02 1987-07-02 CRYSTALLINE HYDRATE OF 7SS - ((Z) -2- (2-AMINOTHIAZOL-4-YL) -4-CARBOXYBUT-2-ENOYLAMINO) -3-CEPHEM-4-CARBONIC ACID AND COMPOSITION CONTAINING THIS
PH35485A PH24474A (en) 1986-09-12 1987-07-02 A crystalline hydrate of oral cephalosporin
AU75040/87A AU594167B2 (en) 1986-07-02 1987-07-02 A crystalline hydrate of oral cephalosporin and its composition
CN87105009A CN1015106B (en) 1986-07-02 1987-07-02 Process for preparing crystalline hydrate of oral cephalosporin
ES8703123A ES2008759A6 (en) 1986-07-02 1987-11-02 Crystalline hydrate of oral cephalosporin and its composition
SU874203950A RU1829932C (en) 1986-07-02 1987-12-30 Method for producing solid gelatin capsules of medicinal preparations
US07/275,093 US4933443A (en) 1986-07-02 1988-11-21 Method for preparing crystalline hydrate of oral celphalosporin and its composition
US07/478,278 US5017380A (en) 1986-07-02 1990-02-09 Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
AT0045890A AT396652B (en) 1986-07-02 1990-02-27 Process for the preparation of hard gelatin capsule compositions
NO911964A NO303264B1 (en) 1986-07-02 1991-05-22 Process for the preparation of a stable capsule preparation
NO921401A NO921401D0 (en) 1986-07-02 1992-04-09 PROCEDURE FOR PREPARING A STABLE CAPSULAR PREPARATION
FI923126A FI95349C (en) 1986-07-02 1992-07-07 Process for the preparation of a gelatin capsule containing 7 - [(Z) -2- (2-aminothiazol-4-yl) -4-carboxybut-2-enoylamino] -3-cephem-4-carboxylic acid
HK478/93A HK47893A (en) 1986-07-02 1993-05-20 A crystalline oral cephalosporin hydrate and its compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21626086A JPH0717651B2 (en) 1986-09-12 1986-09-12 Cefalosporin hydrate crystal for oral administration

Publications (2)

Publication Number Publication Date
JPS6372691A true JPS6372691A (en) 1988-04-02
JPH0717651B2 JPH0717651B2 (en) 1995-03-01

Family

ID=16685766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP21626086A Expired - Lifetime JPH0717651B2 (en) 1986-07-02 1986-09-12 Cefalosporin hydrate crystal for oral administration

Country Status (3)

Country Link
JP (1) JPH0717651B2 (en)
PH (1) PH24474A (en)
SU (1) SU1560057A3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100512870B1 (en) * 2002-10-15 2005-09-07 주식회사 엔지켐 Method for producing 7α-methoxycephalosporin derivative sodium salt 7-hydrate
JP2012532180A (en) * 2009-07-06 2012-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング BIBW2992, a salt thereof and a method for drying a solid pharmaceutical preparation comprising this active ingredient

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100512870B1 (en) * 2002-10-15 2005-09-07 주식회사 엔지켐 Method for producing 7α-methoxycephalosporin derivative sodium salt 7-hydrate
JP2012532180A (en) * 2009-07-06 2012-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング BIBW2992, a salt thereof and a method for drying a solid pharmaceutical preparation comprising this active ingredient

Also Published As

Publication number Publication date
JPH0717651B2 (en) 1995-03-01
SU1560057A3 (en) 1990-04-23
PH24474A (en) 1990-07-18

Similar Documents

Publication Publication Date Title
NO170889B (en) PROCEDURE FOR PREPARING A STABLE CRYSTALLINE DIET OR TRIHYDRATE OF 7BETA - ((Z) -2- (2-AMINOTIAZOL-4-YL) -4-CARBOXYBUT-2-ENOYLAMINO) -3-CEFEM-4-CARBOXYL
KR100381644B1 (en) 8-alkoxyquinolone carboxylic acid hydrate with excellent stability and preparation method thereof
JPH02167286A (en) Salt of clavulanic acid, and production and use
RU2004108953A (en) POLYMORPHIC FORMS OF RIFAXIMINE, METHODS FOR THEIR PRODUCTION AND THEIR APPLICATION IN MEDICAL DRUGS
JPH0249797A (en) Production of erythromycin a oxime and salt thereof
WO2016098131A2 (en) Improved method for the synthesis of ferric oraganic compounds
JP2021036002A (en) Crystals of 6'-sialyl lactose sodium salt and method for producing the same
JP7528060B2 (en) Novel hydrochloride salt forms of sulfonamide kinase inhibitors
WO2002090363A1 (en) ANHYDROUS CRYSTAL OF ss-LACTAM COMPOUND AND METHOD FOR PREPARATION THEREOF
JPS6372691A (en) Hydrated cephalosporin crystal for oral administration
JP3793583B2 (en) Antibacterial compound crystals
WO2002092605A1 (en) CRYSTAL OF HYDRATE OF ß-LACTAM COMPOUND
JPS6155901B2 (en)
US4076745A (en) Process for calcium salts α-ketocarboxylic acids
JPS60120886A (en) Crystal of cephemcarboxylic acid sodium salt
WO2002030943A1 (en) Erythromycin derivative having novel crystal structures and processes for their production
JPH07508495A (en) Oxytetracycline purification method and intermediates
JP3755908B2 (en) Crystallization of cephalosporin compounds
JP3924027B2 (en) Sodium orthohydroxymandelate / phenol / water complex, process for its preparation and use for the separation of sodium orthohydroxymandelate
JP4817737B2 (en) Method for producing calcium L-aspartate crystals
JPH04261189A (en) Production of tin trifluoromethanesulfonate
US4124636A (en) Method of preparing monopotassium L-malate and its monohydrate
SU565507A1 (en) Method of preparing modified lignin
JP6254586B2 (en) Arbekacin derivatives and their production and use
JP2917495B2 (en) Method for producing optically active 1,2-propanediamine

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term